Boston, MA -- (ReleaseWire) -- 05/23/2014 -- Although Mexico has made great efforts to improve its regulatory framework and create a more hospitable business environment to entice pharmaceutical companies, it is still hard for multinationals to fully materialise their commercial benefit due to the significant market share of generic drugs. We believe that generic drugs will be a key element of Mexico's healthcare modernisation. They are a very effective way in which the government can control public spending while trying to increase medicines coverage. However, in the long term, Mexico's improving private health insurance sector and potentially significant investment from the government will boost patented drug consumption in the country.
View Full Report Details and Table of Contents
Headline Expenditure Projections
- Pharmaceuticals: MXN187.4bn (USD14.7bn) in 2013 to MXN204.1bn (USD16.3bn) in 2014; +8.9% in local currency terms and +10.8% in US dollar terms. Forecast decreased from Q214 due to increasing generic competition.
- Healthcare: MXN1,044.3bn (USD81.8bn) in 2013 to MXN1,139.8bn (USD90.8bn) in 2014; +9.1% in local currency terms and +11.0% in US dollar terms. Forecast increased from Q214 due to more optimistic macroeconomic forecasts.
Mexico scores 60.6 in BMI's Pharmaceutical and Healthcare Risk/Reward Rating (RRR), making it the fourth-most attractive pharmaceutical market in the region.
Key Trends And Developments
- Mexico's Federal Commission for Protection Against Health Risks (COFEPRIS) signed an agreement to promote innovation, under which the registration approval timeline for new molecules will be reduced to 60 working days from the previous 360 days.
- COFEPRIS changed its clinical research protocol to reduce the pre-approval time for clinical trials from three months to one month. COFEPRIS has also authorised the National Institutes of Health, as well as speciality hospitals, to assist its clinical trial evaluation process.
- Indian drugmaker Lupin revealed its acquisition of a 100% equity stake in Laboratorios Grin (Grin), a leading Mexican pharmaceutical company specialising in branded ophthalmic products.
- Genomma acquired a 50% interest in Marzam Commercial and Industrial Group for MXN600mn (USD45.15mn).
- GlaxoSmithKline Mexico's vice president and general manager, Jose Alberto Pena, told a local media organisation that the company has accelerated product registration in Mexico since November 2012. February
- Mexico's secretary of Health, Mercedes Juan Lopez, stated that the federal agency plans to reduce out-ofpocket spending on healthcare and improve the quality of service through Seguro Popular in Mexico. The Health secretary has also planned to reform Seguro Popular to address issues such as the fragmented healthcare system and inefficient use of resources in Mexico.
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Healthcare research reports at Fast Market Research
You may also be interested in these related reports:
- Thailand Pharmaceuticals & Healthcare Report Q3 2014
- Nigeria Pharmaceuticals & Healthcare Report Q3 2014
- Australia Pharmaceuticals & Healthcare Report Q3 2014
- Central America Pharmaceuticals & Healthcare Report Q3 2014
- Croatia Pharmaceuticals & Healthcare Report Q3 2014
- Algeria Pharmaceuticals & Healthcare Report Q3 2014
- Latvia Pharmaceuticals & Healthcare Report Q3 2014
- CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - South Korea
- Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2013
- Partnerships, Licensing, Investments and M&A Deals and Trends for February 2014 in Pharmaceuticals